Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Biora Therapeutics Inc

Company price
None USD 0.00(0%)
Last update at 2026-04-30T21:06:31.970208Z
Market Cap
0.99M
P/E
0.61

Momentum Score

…

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California. On December 27, 2024, Biora Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.15
Low
0.22
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.86M
Revenue Per Share
0.00
Gross Profit TTM
1.25M
Debt / Equity
-0.47
ROE
-
Net Debt
32.22M
ROCE
360.89%
Diluted EPS TTM
0.36

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -124.42M -49.25M -178.64M -230.06M -148.74M
Net income -124.11M -48.83M -178.52M -192.53M -148.04M
Selling general administrative 38.11M 38.04M 68.54M 75.44M 61.32M
Selling and marketing expenses - - 4.76M 52.89M 58.89M
Gross profit 0.00M 0.30M 1.25M -19.12M 43.49M
Reconciled depreciation 0.60M 0.91M 1.44M 5.06M 6.35M
Ebit -114.61M -61.78M -117.84M -200.25M -140.12M
Ebitda -114.05M -59.16M -63.68M -195.19M -133.19M
Depreciation and amortization 0.56M 2.62M 54.16M 5.06M 6.92M
Operating income -67.14M -61.78M -117.84M -195.19M -140.12M
Other operating expenses 67.15M 62.09M 119.08M 269.50M 284.10M
Interest expense 9.81M 10.99M 12.64M 34.87M 9.20M
Tax provision 0.26M -0.42M -0.12M -37.53M -0.71M
Interest income - - - - 0.57M
Net interest income -10.66M -10.99M -12.64M -34.87M -8.62M
Income tax expense -0.09M -0.42M -0.12M -37.53M -0.71M
Total revenue 0.00M 0.30M 1.25M 74.31M 143.99M
Total operating expenses 67.15M 62.09M 119.08M 176.07M 183.61M
Cost of revenue 0.56M - 0.00M 93.43M 100.49M
Total other income expense net -57.28M 12.53M -60.80M -34.87M -8.62M
Discontinued operations - - -68.89M -87.44M -87.44M
Net income from continuing ops -122.17M -48.83M -178.52M -192.53M -148.04M
Net income applicable to common shares - - -247.41M -192.80M -228.83M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 31.21M 53.52M 108.84M 154.44M 101.73M
Intangible assets - - - 3.84M 4.77M
Other current assets 3.03M 4.20M 7.23M 9.36M 1.37M
Total liab 132.64M 155.81M 193.81M 261.43M 185.60M
Total stockholder equity -101.42M -102.29M -84.98M -106.99M -83.87M
Other current liab 56.72M 18.76M 52.59M 54.30M 6.04M
Common stock 0.03M 0.01M 0.15M 0.06M 0.04M
Capital stock 0.03M 0.01M 0.15M 0.06M 0.04M
Retained earnings -950.96M -826.84M -788.69M -541.27M -348.48M
Other liab - - 5.81M 28.56M 12.86M
Good will 6.07M 6.07M 6.07M 6.22M 6.22M
Other assets 0.00M - 0.33M 13.92M 0.20M
Cash 15.21M 30.49M 88.40M 92.08M 33.04M
Total current liabilities 62.97M 23.30M 61.61M 72.67M 100.34M
Current deferred revenue 0.54M 0.05M 0.30M 0.38M 77.57M
Net debt 32.22M 97.33M 38.01M 70.23M 40.33M
Short term debt 2.87M 0.89M 0.01M 0.58M 0.97M
Short long term debt 1.98M - 0.01M 0.27M 0.24M
Short long term debt total 47.43M 127.81M 126.40M 162.31M 73.37M
Other stockholder equity 849.51M 724.55M 703.56M 434.22M 264.57M
Property plant equipment - - 4.01M 8.11M 15.89M
Total current assets 19.07M 38.12M 98.43M 126.34M 74.65M
Long term investments 3.00M 6.00M - - -
Net tangible assets - - -91.05M -113.07M -94.97M
Short term investments - - - - 0.00M
Net receivables 0.83M 0.83M 0.65M 12.68M 22.82M
Long term debt 43.74M 127.81M 126.39M 161.68M 72.05M
Inventory - 2.60M 2.15M 12.22M 10.94M
Accounts payable 2.84M 3.61M 8.71M 17.41M 15.75M
Accumulated other comprehensive income 0.00M - - - -
Non currrent assets other 0.30M 0.20M 0.33M 0.20M 0.20M
Non current assets total 12.14M 15.41M 10.41M 28.10M 27.08M
Capital lease obligations 1.71M 1.49M 0.01M 0.36M 1.08M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.10M -0.79M -1.24M -4.94M 20.25M
Change to liabilities - - -8.69M 2.83M 4.38M
Total cashflows from investing activities 2.44M - -1.24M -4.94M 16.52M
Net borrowings 10.00M - -1.64M 98.97M -1.27M
Total cash from financing activities 30.78M 7.30M 165.05M 229.72M 73.64M
Change to operating activities - - -17.26M -63.24M -16.56M
Net income -124.11M -38.16M -178.52M -192.53M -148.04M
Change in cash -15.28M -57.91M -3.68M 59.03M -15.96M
Begin period cash flow 30.49M 88.40M 92.08M 33.04M 49.01M
End period cash flow 15.21M 30.49M 88.40M 92.08M 33.04M
Total cash from operating activities -48.50M -64.42M -167.49M -165.74M -106.12M
Issuance of capital stock 15.62M 9.01M 46.78M 137.74M 79.59M
Depreciation 0.56M 0.91M 1.44M 5.06M 6.35M
Other cashflows from investing activities 2.55M - -0.39M -1.07M -1.07M
Dividends paid - - - 0.00M 4.50M
Change to inventory - - - -1.43M -3.86M
Change to account receivables -0.00M - - 9.51M 3.43M
Sale purchase of stock - 0.10M - - 79.04M
Other cashflows from financing activities 2.64M -1.80M 119.92M 114.27M -0.18M
Change to netincome - - 102.78M 81.47M 42.61M
Capital expenditures 0.10M 0.79M 0.85M 4.94M 3.73M
Change in working capital 8.62M -4.65M -25.86M -51.17M 32.65M
Stock based compensation 16.48M 7.80M 11.96M 10.67M 2.38M
Other non cash items 49.97M -30.32M 1.57M 3.66M 0.54M
Free cash flow -48.60M -65.21M -168.34M -170.69M -109.85M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Biora Therapeutics Inc

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California. On December 27, 2024, Biora Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

4330 La Jolla Village Drive, San Diego, CA, United States, 92122

833 727 2841

58

Name Title Year Born
Mr. Aditya P. Mohanty M.B.A. CEO & Director 1967
Mr. Eric d'Esparbes Chief Financial Officer 1968
Mr. Clarke Neumann J.D. Gen. Counsel & Sec. 1964
Eric Fox VP of Fin. & Accounting & Treasurer NA
Mr. Troy Seelye Chief Information Officer 1964
Mr. George Gianakopoulos Sr. VP of Sales 1961
Ms. Robyn Hatton Head of HR NA
Mr. Kevin Howe Ph.D. Sr. VP of Strategic Operations NA
Dr. Sharat Singh Ph.D. Head of Research 1959
Dr. Paul Shabram M.B.A. Head of Technical Operations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…